Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.140
+0.140 (4.67%)
At close: Nov 18, 2025, 4:00 PM EST
3.160
+0.020 (0.64%)
After-hours: Nov 18, 2025, 4:00 PM EST
Company Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN).
The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.
Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Grace Therapeutics, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Prashant Kohli |
Contact Details
Address: 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 United States | |
| Phone | 609-322-1602 |
| Website | gracetx.com |
Stock Details
| Ticker Symbol | GRCE |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001444192 |
| ISIN Number | US00439U1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Prashant Kohli | Chief Executive Officer and Director |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Vice President of Clinical Operations |
| Robert J. DelAversano CPA | Vice President of Finance and Principal Financial and Accounting Officer |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 17, 2025 | 10-Q/A | [Amend] Quarterly report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Oct 23, 2025 | 8-K | Current Report |
| Sep 18, 2025 | 8-K | Current Report |
| Sep 12, 2025 | 8-K | Current Report |
| Aug 27, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | 8-K | Current Report |